Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study
Objective. To evaluate the effect of anti-TNF agents plus synthetic disease modifying antirheumatic drugs (DMARDs) versus DMARDs alone for ankylosing spondylitis (AS) with reduced pulmonary function vital capacity (FVC%). Methods. In an observational study, we included AS who had FVC% <80% at bas...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/980147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565016249761792 |
|---|---|
| author | Alberto Daniel Rocha-Muñoz Aniel Jessica Leticia Brambila-Tapia María Guadalupe Zavala-Cerna José Clemente Vásquez-Jiménez Liliana Faviola De la Cerda-Trujillo Mónica Vázquez-Del Mercado Norma Alejandra Rodriguez-Jimenez Valeria Díaz-Rizo Viviana Díaz-González Ernesto German Cardona-Muñoz Ingrid Patricia Dávalos-Rodríguez Mario Salazar-Paramo Jorge Ivan Gamez-Nava Arnulfo Hernan Nava-Zavala Laura Gonzalez-Lopez |
| author_facet | Alberto Daniel Rocha-Muñoz Aniel Jessica Leticia Brambila-Tapia María Guadalupe Zavala-Cerna José Clemente Vásquez-Jiménez Liliana Faviola De la Cerda-Trujillo Mónica Vázquez-Del Mercado Norma Alejandra Rodriguez-Jimenez Valeria Díaz-Rizo Viviana Díaz-González Ernesto German Cardona-Muñoz Ingrid Patricia Dávalos-Rodríguez Mario Salazar-Paramo Jorge Ivan Gamez-Nava Arnulfo Hernan Nava-Zavala Laura Gonzalez-Lopez |
| author_sort | Alberto Daniel Rocha-Muñoz |
| collection | DOAJ |
| description | Objective. To evaluate the effect of anti-TNF agents plus synthetic disease modifying antirheumatic drugs (DMARDs) versus DMARDs alone for ankylosing spondylitis (AS) with reduced pulmonary function vital capacity (FVC%). Methods. In an observational study, we included AS who had FVC% <80% at baseline. Twenty patients were taking DMARDs and 16 received anti-TNF + DMARDs. Outcome measures: changes in FVC%, BASDAI, BASFI, 6-minute walk test (6MWT), Borg scale after 6MWT, and St. George’s Respiratory Questionnaire at 24 months. Results. Both DMARDs and anti-TNF + DMARDs groups had similar baseline values in FVC%. Significant improvement was achieved with anti-TNF + DMARDs in FVC%, at 24 months, when compared to DMARDs alone (P=0.04). Similarly, patients in anti-TNF + DMARDs group had greater improvement in BASDAI, BASFI, Borg scale, and 6MWT when compared to DMARDs alone. After 2 years of follow-up, 14/16 (87.5%) in the anti-TNF + DMARDs group achieved the primary outcome: FVC% ≥80%, compared with 11/20 (55%) in the DMARDs group (P=0.04). Conclusions. Patients with anti-TNF + DMARDs had a greater improvement in FVC% and cardiopulmonary scales at 24 months compared with DMARDs. This preliminary study supports the fact that anti-TNF agents may offer additional benefits compared to DMARDs in patients with AS who have reduced FVC%. |
| format | Article |
| id | doaj-art-499897296f314dcb9bfd39f02293c380 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-499897296f314dcb9bfd39f02293c3802025-02-03T01:09:34ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/980147980147Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational StudyAlberto Daniel Rocha-Muñoz0Aniel Jessica Leticia Brambila-Tapia1María Guadalupe Zavala-Cerna2José Clemente Vásquez-Jiménez3Liliana Faviola De la Cerda-Trujillo4Mónica Vázquez-Del Mercado5Norma Alejandra Rodriguez-Jimenez6Valeria Díaz-Rizo7Viviana Díaz-González8Ernesto German Cardona-Muñoz9Ingrid Patricia Dávalos-Rodríguez10Mario Salazar-Paramo11Jorge Ivan Gamez-Nava12Arnulfo Hernan Nava-Zavala13Laura Gonzalez-Lopez14Universidad de Colima, 28046 Colima, COL, MexicoCentro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoDepartamento de Inmunología, Facultad de Medicina, Universidad Autonoma de Guadalajara, 44670 Guadalajara, JAL, MexicoCentro Universitario de Investigacion Biomedica, Universidad de Colima, 28040 Colima, COL, MexicoCoordinación de Investigacion, Division de Cirugia, Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, 44280 Guadalajara, JAL, MexicoInstituto de Investigación en Reumatologia y del Sistema Musculoesqueletico, CUCS, Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoCentro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoCentro Universitario de Investigacion Biomedica, Universidad de Colima, 28040 Colima, COL, MexicoCentro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoDepartamento de Fisiologia, CUCS, Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoDivisión de Genetica, Centro de Investigacion Biomedica de Occidente, IMSS, 44340 Guadalajara, JAL, MexicoDepartamento de Fisiologia, CUCS, Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoCentro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoUnidad de Investigacion en Epidemiologia, Clinica, Hospital de Especialidades Centro Medico Nacional de Occidente (CMNO), IMSS, 44340 Guadalajara, JAL, MexicoCentro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, 44340 Guadalajara, JAL, MexicoObjective. To evaluate the effect of anti-TNF agents plus synthetic disease modifying antirheumatic drugs (DMARDs) versus DMARDs alone for ankylosing spondylitis (AS) with reduced pulmonary function vital capacity (FVC%). Methods. In an observational study, we included AS who had FVC% <80% at baseline. Twenty patients were taking DMARDs and 16 received anti-TNF + DMARDs. Outcome measures: changes in FVC%, BASDAI, BASFI, 6-minute walk test (6MWT), Borg scale after 6MWT, and St. George’s Respiratory Questionnaire at 24 months. Results. Both DMARDs and anti-TNF + DMARDs groups had similar baseline values in FVC%. Significant improvement was achieved with anti-TNF + DMARDs in FVC%, at 24 months, when compared to DMARDs alone (P=0.04). Similarly, patients in anti-TNF + DMARDs group had greater improvement in BASDAI, BASFI, Borg scale, and 6MWT when compared to DMARDs alone. After 2 years of follow-up, 14/16 (87.5%) in the anti-TNF + DMARDs group achieved the primary outcome: FVC% ≥80%, compared with 11/20 (55%) in the DMARDs group (P=0.04). Conclusions. Patients with anti-TNF + DMARDs had a greater improvement in FVC% and cardiopulmonary scales at 24 months compared with DMARDs. This preliminary study supports the fact that anti-TNF agents may offer additional benefits compared to DMARDs in patients with AS who have reduced FVC%.http://dx.doi.org/10.1155/2015/980147 |
| spellingShingle | Alberto Daniel Rocha-Muñoz Aniel Jessica Leticia Brambila-Tapia María Guadalupe Zavala-Cerna José Clemente Vásquez-Jiménez Liliana Faviola De la Cerda-Trujillo Mónica Vázquez-Del Mercado Norma Alejandra Rodriguez-Jimenez Valeria Díaz-Rizo Viviana Díaz-González Ernesto German Cardona-Muñoz Ingrid Patricia Dávalos-Rodríguez Mario Salazar-Paramo Jorge Ivan Gamez-Nava Arnulfo Hernan Nava-Zavala Laura Gonzalez-Lopez Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study Journal of Immunology Research |
| title | Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study |
| title_full | Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study |
| title_fullStr | Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study |
| title_full_unstemmed | Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study |
| title_short | Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study |
| title_sort | influence of anti tnf and disease modifying antirheumatic drugs therapy on pulmonary forced vital capacity associated to ankylosing spondylitis a 2 year follow up observational study |
| url | http://dx.doi.org/10.1155/2015/980147 |
| work_keys_str_mv | AT albertodanielrochamunoz influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT anieljessicaleticiabrambilatapia influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT mariaguadalupezavalacerna influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT joseclementevasquezjimenez influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT lilianafavioladelacerdatrujillo influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT monicavazquezdelmercado influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT normaalejandrarodriguezjimenez influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT valeriadiazrizo influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT vivianadiazgonzalez influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT ernestogermancardonamunoz influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT ingridpatriciadavalosrodriguez influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT mariosalazarparamo influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT jorgeivangameznava influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT arnulfohernannavazavala influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy AT lauragonzalezlopez influenceofantitnfanddiseasemodifyingantirheumaticdrugstherapyonpulmonaryforcedvitalcapacityassociatedtoankylosingspondylitisa2yearfollowupobservationalstudy |